Impact of tocilizumab use on infectious complications among recipients of CAR T cells who developed mild cytokine release syndrome.
Study #: CV20-03
Study Status: Published
Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?
Nikiforow S, Mansour M, Hu Z-H, Horowitz MM, Riches M, Hematti P, Turtle CJ, Zhang M-J, Perales M-A, Pasquini MC, Frigault MJ.
Blood. 2020, Jul 02: 136(1): 136(1):137-139. doi: 10.1182/blood.2020006216. Epub 2020, May 25. PMCID:PMC7332891.
PMID: 32457999
Abstract